IQ EQ FUND MANAGEMENT IRELAND Ltd Sells 2,635 Shares of Cencora, Inc. $COR

IQ EQ FUND MANAGEMENT IRELAND Ltd lowered its position in shares of Cencora, Inc. (NYSE:COR) by 48.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,822 shares of the company’s stock after selling 2,635 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Cencora were worth $882,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC grew its position in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares in the last quarter. Cloud Capital Management LLC bought a new position in Cencora in the 3rd quarter worth about $31,000. Westside Investment Management Inc. raised its holdings in shares of Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after acquiring an additional 70 shares in the last quarter. Finally, Copia Wealth Management boosted its position in shares of Cencora by 505.0% during the 3rd quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after acquiring an additional 101 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of Cencora stock opened at $359.15 on Friday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.55 and a current ratio of 0.92. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54. The company has a fifty day moving average of $345.91 and a 200-day moving average of $325.92. The stock has a market capitalization of $69.67 billion, a price-to-earnings ratio of 43.17, a price-to-earnings-growth ratio of 1.63 and a beta of 0.68.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period in the previous year, the firm posted $3.73 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Q1 2026 earnings call highlighted strong U.S. growth that offset international headwinds; management commentary helped support the upbeat tone after results. Cencora Inc (COR) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Cencora closed its deal with OneOncology; coverage of the terms characterizes the agreement as reflecting trust between parties, which supports the company’s oncology services strategy and potential revenue synergies. As Cencora Closes With OneOncology
• Neutral Sentiment: Evercore ISI set a new $420 price target (down from $440) but kept an “outperform” rating — the target implies meaningful upside from current levels despite the trim. Cencora Given New $420.00 Price Target at Evercore ISI
• Neutral Sentiment: Market write-ups and stock-flow coverage are highlighting the mix of EPS beats and revenue dynamics as reasons for the intraday move, keeping attention on upcoming guidance and international performance. Cencora stock trades up, here is why
• Negative Sentiment: Cencora missed Q4 CY2025 revenue estimates, which tempers enthusiasm from the EPS beat and raises questions about near-term revenue momentum. Cencora misses Q4 revenue estimates
• Negative Sentiment: Recent intraday coverage noted the stock underperformed peers on Wednesday, suggesting investors are watching competitive execution and margin trends across the sector. Cencora underperforms competitors

Wall Street Analyst Weigh In

Several research analysts recently weighed in on COR shares. Barclays initiated coverage on shares of Cencora in a research report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective on the stock. Bank of America decreased their price target on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. Mizuho lifted their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Robert W. Baird set a $415.00 target price on shares of Cencora in a research report on Tuesday, January 13th. Finally, JPMorgan Chase & Co. raised their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $394.75.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 20,316 shares of company stock worth $7,151,265 in the last ninety days. 0.38% of the stock is owned by insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.